Research programme: CX 1000 series - CyleneAlternative Names: CX 1000 series; CX 1322
Latest Information Update: 30 Apr 2007
At a glance
- Originator University of Arizona
- Developer Cylene Pharmaceuticals; University of Arizona
- Class Small molecules
- Mechanism of Action Genetic transcription inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer